154 related articles for article (PubMed ID: 25283839)
1. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.
Crins ND; Röver C; Goralczyk AD; Friede T
Pediatr Transplant; 2014 Dec; 18(8):839-50. PubMed ID: 25283839
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies.
Goralczyk AD; Hauke N; Bari N; Tsui TY; Lorf T; Obed A
Hepatology; 2011 Aug; 54(2):541-54. PubMed ID: 21520208
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
4. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials.
Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
J Heart Lung Transplant; 2008 Aug; 27(8):835-42. PubMed ID: 18656795
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.
Sun ZJ; Du X; Su LL; Zhang XD; Wang W
Transplant Proc; 2015 Oct; 47(8):2439-45. PubMed ID: 26518947
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis.
Zhang Y; Jin W; Cai X
Ann Med; 2017 Aug; 49(5):365-376. PubMed ID: 27813419
[TBL] [Abstract][Full Text] [Related]
9. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
10. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
11. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
[TBL] [Abstract][Full Text] [Related]
12. Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation.
Ahsan N
Minerva Urol Nefrol; 2003 Mar; 55(1):67-79. PubMed ID: 12773968
[TBL] [Abstract][Full Text] [Related]
13. Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: A retrospective cohort study.
Xue M; Lv C; Chen X; Huang X; Sun Q; Wang T; Liang J; Zhang Y; He S; Gao J; Zhou J; Yu M; Fan J; Gao X
J Diabetes; 2016 Jul; 8(4):579-87. PubMed ID: 26588180
[TBL] [Abstract][Full Text] [Related]
14. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
[TBL] [Abstract][Full Text] [Related]
15. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
Orr DW; Portmann BC; Knisely AS; Stoll S; Rela M; Muiesan P; Bowles MJ; Heaton ND; O'Grady JG; Heneghan MA
Transplant Proc; 2005 Dec; 37(10):4373-9. PubMed ID: 16387124
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.
Webster AC; Playford EG; Higgins G; Chapman JR; Craig JC
Transplantation; 2004 Jan; 77(2):166-76. PubMed ID: 14742976
[TBL] [Abstract][Full Text] [Related]
17. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients.
Taber DJ; McGillicuddy JW; Bratton CF; Rohan VS; Nadig S; Dubay D; Baliga PK
Ann Surg; 2017 Sep; 266(3):450-456. PubMed ID: 28654544
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
19. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis.
Ali H; Soliman KM; Shaheen I; Kim JJ; Kossi ME; Sharma A; Pararajasingam R; Halawa A
Int Urol Nephrol; 2020 Apr; 52(4):791-802. PubMed ID: 32170593
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation.
Taber DJ; Weimert NA; Henderson F; Lin A; Bratton CF; Chavin KD; Baliga PK
Transplant Proc; 2008 Dec; 40(10):3401-7. PubMed ID: 19100399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
